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pince the discovery of brain natriuretic peptide (BNP) in
988 (1), both BNP and its inactive metabolite N-terminal
ro–B-type natriuretic peptide (NT-proBNP) have played a
rominent role in furthering our understanding of cardio-
ascular pathophysiology. Clinically, both assays now have a
rmly established role in the diagnosis of acute heart failure,
nd have been incorporated in the most recent American
ollege of Cardiology Foundation/American Heart Asso-
iation guidelines for use in the urgent care setting, when
he diagnosis of heart failure is uncertain (2). The role of
hese biomarkers in prognostication and risk prediction is
lso expanding. Prior studies have shown that BNP and/or
T-proBNP are independent predictors of mortality in
atients with stable coronary artery disease (3), acute coro-
ary syndromes (4), and congestive heart failure (5). The
tility of testing in the general population, however, remains
ess well established. In the Framingham Heart Study, BNP
alues above the 80th percentile (but well below thresholds
sed to diagnose heart failure) were independently associ-
ted with death and cardiovascular events in subjects with-
ut prevalent heart failure (6). Similar results were found in
community-based cohort from Olmsted County (7).
See page 2140
McKie et al. (8) now report an extension of data from
lmsted County in this issue of the Journal. Whereas their
revious study reported overall results for the full cohort of
,991 participants, this new analysis takes on a different and
ovel focus. Rather than examining the overall sample, partic-
pants were divided into subgroups. The healthy normal
ubgroup included participants without heart disease or its
ajor risk factors including hypertension, diabetes mellitus,
hronic obstructive pulmonary disease, history of cardiovascu-
ar drug use, peripheral vascular disease, hyperlipidemia, atrial
Editorials published in the Journal of the American College of Cardiology reflect the
iews of the authors and do not necessarily represent the views of JACC or the
merican College of Cardiology.t
From the National Heart, Lung, and Blood Institute’s Center for Population
tudies, and the Framingham Heart Study, Framingham, Massachusetts.brillation, or structural heart disease on echocardiography.
he remaining subjects with clinical heart disease, 1 or more
eart disease risk factors, or subclinical heart abnormalities on
chocardiography were classified as stage A/B heart failure.
he authors then examined the utility of an NT-proBNP value
xceeding the 80th percentile (age- and sex-specific) as a
redictor of all-cause mortality and cardiovascular events in
ach subgroup. Interestingly, NT-proBNP was not predictive
f clinical outcomes in the healthy normal subgroup, whereas
n the stage A/B heart failure subgroup, mortality and incident
eart failure, cerebrovascular accident, and myocardial infarc-
ion were all higher in patients with elevated NT-proBNP
evels.
While it is not surprising that NT-proBNP was not asso-
iated with cardiovascular outcomes in the healthy normal
ubgroup in whom the pre-test probability of an event is
lready exceedingly low based on the absence of traditional
linical and echocardiographic risk factors, this still represents
n important finding. Within the larger field of cardiovascular
iomarkers, identifying persons who would not benefit from a
iagnostic test may be just as important as knowing who to
est, making this study unique and novel in that regard.
owever, several points need to be considered before convinc-
ngly rejecting any role of natriuretic peptide measurements in
he general “healthy” population. First, the healthy normal
ubgroup in this study differs from the general healthy popu-
ation, because subjects with subclinical echocardiographic
bnormalities were excluded (i.e., they were already pre-
creened with echocardiography, a more expensive modality to
etect subclinical structural heart disease). We know that
chocardiographic features such as asymptomatic left ventric-
lar systolic dysfunction portend a worse cardiovascular prog-
osis (9), and treatment with angiotensin-converting enzyme
nhibitors has been shown to prevent progression to overt heart
ailure in this patient population (10). Yet, it is not routine to
creen the general population with echocardiography because
f cost considerations. Could natriuretic peptide levels be a
seful and cost-effective screening tool in apparently healthy
ersons, when echocardiography has not already screened out
hose with structural abnormalities? This question remains
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May 11, 2010:2148–9 BNP Testing in the General Populationnanswered by this study, and should be considered before
ismissing the utility of natriuretic peptides as a screening tool
n the general population. Finally, it is also important to
onsider that with just over 700 healthy normal participants,
he study may be underpowered to detect a potential moderate
ifference in outcomes as a function of NT-proBNP levels
ithin the healthy normal subgroup. Thus, it may be some-
hat premature to definitively conclude that there is no utility
o natriuretic peptide measurements in the general population.
While the identification of a subgroup in which NT-
roBNP testing may not be indicated is novel, its significance
n populations akin to the stage A/B heart failure subgroup
dentified in this study has been examined previously. In the
resent study, NT-proBNP was an independent predictor of
ardiovascular events in participants with stage A/B heart
ailure, a group that included people with prevalent coronary
rtery disease, in whom BNP testing already has been shown to
redict prognosis (11). While natriuretic peptides are clearly
ssociated with cardiovascular outcomes in high-risk popula-
ions, the incremental benefit of NT-proBNP testing to
lready known clinical and echocardiographic risk factors
emains unclear. Prior studies in risk prediction have focused
n the combination of several biomarkers and their potential
ncremental utility in risk prediction, with mixed results. In the
ramingham Heart Study (12), the addition of a combination
f 10 biomarkers (including natriuretic peptides) added only
oderately to standard risk factors in persons free of major
ardiovascular disease at baseline. In contrast, in a study by
ethelius et al. (13), there appeared to be significant improve-
ent in cardiovascular risk stratification in a cohort of elderly
en from a combination of 4 biomarkers, although men with
revalent disease at baseline were included.
The present study (8) demonstrates a negligible change in
he c-statistic with the addition of natriuretic testing to a model
ith clinical risk factors for each of the clinical outcomes.
urthermore, the incremental increase in integrated discrimi-
ation improvement ranged from 0.5% to 1.3% for the various
ardiovascular outcomes, which, while statistically significant
n a model including only clinical but not echocardiographic
actors, is a very modest increase, and so the true utility and
ost effectiveness of natriuretic peptide testing in this group
ith a substantial burden of risk factors remains to be eluci-
ated. It may be that incremental improvement in risk predic-
ion with natriuretic peptide testing is limited to a subset of
atients within the stage A/B heart failure subgroup, given a
elatively heterogenous group with respect to clinical risk
actors. For example, in participants with known coronary
rtery disease for whom echocardiography is already indicated
nd aids in risk stratification, additional testing with NT-
roBNP may not be cost effective. However, it certainly is
ossible that in participants with hypertension or diabetes
ellitus for whom screening echocardiography may not be
ndicated in routine clinical practice, natriuretic peptide testing
ay aid in risk stratification and may be more cost effectivehan echocardiography in that setting. yWith the growing burden of heart failure and its associ-
ted morbidity and mortality in the U.S., identifying high-
isk patients before the development of overt symptoms is
n important clinical challenge, as it may facilitate early
revention efforts at a time when intervention is most likely
o succeed. Understanding the role of biomarkers as tools to
dentify high-risk groups will allow us to effectively target
revention strategies, and the present study by McKie et al.
8) is an important step in the right direction. By identifying
ow-risk groups in which NT-proBNP testing is not infor-
ative, the role of natriuretic peptides in cardiovascular risk
tratification will become slightly less complex.
eprint requests and correspondence: Dr. Daniel Levy, NHLBI’s
ramingham Heart Study, 73 Mount Wayte Avenue, Suite 2,
ramingham, Massachusetts 01702. E-mail: levyd@nhlbi.nih.gov.
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